NewAmsterdam Pharma Co N.V. (NAMS) Stock Research
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
Latest price: 23.2 · Sector: Healthcare
Recent Insider Transactions
| Insider | Type | Date | Value |
|---|---|---|---|
| Kastelein Johannes Jacob Pieter | sell | 2026-09-30 | 1257657.38 |
| Davidson Michael H. | buy | 2026-09-14 | 226500 |
| Smither John W | sell | 2026-09-04 | 40512 |
| Kastelein Johannes Jacob Pieter | sell | 2026-08-24 | 3363750 |
| Kooij Louise Frederika | sell | 2026-07-20 | 92434.65 |
| Kooij Louise Frederika | sell | 2026-07-20 | 2103192 |
| Kooij Louise Frederika | sell | 2026-07-20 | 990029.25 |
| Kooij Louise Frederika | sell | 2026-06-22 | 1198940 |
| Kooij Louise Frederika | sell | 2026-06-22 | 9219 |
| Kooij Louise Frederika | sell | 2026-05-26 | 2319850 |